BLOOD REVIEWS
Scope & Guideline
Connecting professionals through cutting-edge research.
Introduction
Aims and Scopes
- Hematological Malignancies:
The journal covers a wide range of hematological malignancies including leukemia, lymphoma, and myeloma, focusing on their biology, treatment strategies, and patient management. - Coagulation Disorders:
Research on various coagulation disorders, such as hemophilia, thrombocytopenia, and thrombotic conditions, is a key focus, including novel therapeutic approaches and management strategies. - Transfusion Medicine:
Exploration of transfusion practices, adverse reactions, and the evolving landscape of transfusion-related therapies, including the use of blood products and their clinical implications. - Immunotherapy and Targeted Therapies:
Significant emphasis on the development and application of immunotherapies, CAR T-cell therapy, and targeted treatments in hematological disorders, reflecting the shift towards personalized medicine. - Patient-Centered Care:
The journal highlights the importance of quality of life, patient preferences, and shared decision-making in treatment approaches for hematological diseases. - Emerging Technologies:
Coverage of innovative technologies such as artificial intelligence and genomics in the diagnosis and treatment of hematological conditions, aiming to integrate cutting-edge science into clinical practice.
Trending and Emerging
- Gene Therapy and Genetic Modulation:
There is a growing interest in gene therapy as a potential curative approach for various hematological disorders, including sickle cell disease and hemophilia, highlighting advancements in genetic technologies. - Microbiome and Hematology:
Research on the gut microbiome's role in hematological conditions is on the rise, exploring how dysbiosis may impact disease progression and treatment outcomes, indicating a shift towards understanding systemic influences on hematologic health. - Immunotherapy Innovations:
The emergence of novel immunotherapeutic strategies, including bispecific antibodies and checkpoint inhibitors, is a significant trend, reflecting the ongoing transformation in treatment paradigms for hematological malignancies. - Health Equity and Access to Care:
Increasing publications focus on disparities in hematological care, emphasizing the need for equity in access to innovative therapies, particularly among diverse populations. - Patient-Reported Outcomes and Quality of Life:
There is an increasing emphasis on patient-reported outcomes and quality of life measures in research, underscoring the importance of holistic approaches to patient care in hematology. - Artificial Intelligence in Hematology:
The application of artificial intelligence and machine learning in diagnostics, treatment personalization, and monitoring of hematologic diseases is an emerging theme, indicative of the journal's forward-looking approach.
Declining or Waning
- Traditional Chemotherapy Approaches:
With the rise of targeted therapies and immunotherapies, traditional chemotherapy approaches for hematological malignancies are discussed less frequently, as newer treatments gain prominence. - Basic Hematology:
Fundamental topics in hematology that do not directly relate to clinical or translational research are becoming less common, as the journal increasingly favors articles with direct clinical applications or innovative methodologies. - Epidemiological Studies:
While still important, epidemiological studies focusing on rare conditions or those with limited translational impact are less frequently published, as the journal prioritizes studies that offer immediate clinical relevance. - Classic Diagnostic Techniques:
The focus on traditional diagnostic methods is waning in favor of more advanced techniques, such as genomic profiling and machine learning applications in diagnostics. - Older Treatment Modalities:
The exploration of older treatment modalities, particularly those that have been largely replaced by newer therapies, is less common as the field moves toward more effective and innovative treatment options.
Similar Journals
Hematology
Elevating Hematology: A Platform for Cutting-Edge ResearchHematology is a distinguished open-access journal published by Taylor & Francis Ltd, dedicated to advancing research and knowledge in the field of hematology. Established in 1996, the journal has continually evolved to meet the needs of a growing community of researchers and practitioners, providing a vital platform for disseminating innovative findings and clinical insights. With its impact factor reflecting a robust commitment to quality scholarship, Hematology has achieved a respectable position in its category as evidenced by its Q3 ranking in the Hematology category and ranks #85 out of 137 in the Scopus index, which positions it in the 38th percentile among its peers. The journal’s open-access policy, initiated in 2019, further enhances its reach and accessibility, allowing a broad audience of professionals, researchers, and students to engage with high-quality research without barriers. By covering a wide range of topics related to blood disorders, treatment methodologies, and emerging therapies, Hematology stands as an essential resource for those dedicated to innovation in this critical area of healthcare.
EUROPEAN JOURNAL OF HAEMATOLOGY
Pioneering Discoveries in Blood Disorders and TherapiesEUROPEAN JOURNAL OF HAEMATOLOGY, published by Wiley, serves as a vital resource for experts in the field of hematology, focusing on the latest advancements in blood disorders and therapies. With an ISSN of 0902-4441 and an E-ISSN of 1600-0609, this esteemed journal has been disseminating knowledge since 1986 and continues to thrive, converging its visionary approach through to 2024. Notably, it holds a distinguished Q2 ranking in Hematology and an impressive Q1 ranking in the broader category of Medicine (miscellaneous) as of 2023, highlighting its significant contribution to the scientific community. With a Scopus rank of #45/137 and a 67th percentile in the field, the journal is recognized for its rigorous peer-reviewed research, making it an indispensable publication for researchers, practitioners, and students aiming to stay at the forefront of hematological studies. Though not an open-access journal, it ensures broad accessibility to critical findings via its subscription model, thus fostering an informed and globally engaged audience.
TRANSFUSION MEDICINE AND HEMOTHERAPY
Empowering innovation in hematology and transfusion medicine.TRANSFUSION MEDICINE AND HEMOTHERAPY, published by KARGER, is a prominent journal dedicated to advancing the fields of hematology and transfusion medicine. With an ISSN of 1660-3796 and E-ISSN 1660-3818, this esteemed journal has been a valuable resource for researchers and clinicians since its inception in 1973, with significant publication phases continuing into 2024. It currently holds a Q2 ranking in Hematology and a Q3 ranking in Immunology and Allergy, reflecting its impact and relevance in these critical fields. The journal features original articles, reviews, and clinical studies, presenting cutting-edge research that aids in the development of effective therapies and enhances patient care. Open access options are available, ensuring that crucial findings are accessible to a broad audience. As an important platform for dialogue and advancement in transfusion science, TRANSFUSION MEDICINE AND HEMOTHERAPY supports the global health community's efforts to improve treatment outcomes and foster innovation in medical practices.
Blood Cancer Discovery
Advancing the Frontiers of Hematologic ResearchBlood Cancer Discovery is a premier academic journal published by the American Association for Cancer Research, dedicated to advancing the understanding of hematologic malignancies through cutting-edge research in the fields of oncology, biochemistry, and molecular biology. With an impressive impact factor and recognition as a Q1 journal across multiple disciplines, including cancer research and hematology, Blood Cancer Discovery serves as an essential platform for scholars and practitioners alike, facilitating impactful discourse and dissemination of pioneering findings. This open-access journal, established within the vibrant academic landscape of the United States, aims to bridge gaps in research and foster collaborations to ultimately enhance patient outcomes. Its Scopus rankings demonstrate its vital role in the critical advancement of cancer research and therapeutic development. By inviting contributions from a diverse range of disciplines, Blood Cancer Discovery is poised to drive innovation and inspire future advancements in understanding blood cancers.
Asian Journal of Transfusion Science
Elevating patient care through innovative research.Asian Journal of Transfusion Science, published by WOLTERS KLUWER MEDKNOW PUBLICATIONS, is a prominent open-access journal dedicated to the interdisciplinary fields of hematology and immunology. With an ISSN of 0973-6247 and E-ISSN 1998-3565, it serves as a crucial platform for researchers, clinicians, and students from around the globe, facilitating the dissemination of high-quality, peer-reviewed research. Established in 2007, the journal has consistently aimed to advance scientific knowledge in transfusion practices, enhancing patient care and safety in transfusion medicine. Despite its recent categorization in the Q4 quartile within both Hematology and Immunology, the journal is making strides toward greater visibility in the academic community, with plans for expanded reach and increased citation impact. With its commitment to open-access publishing, the Asian Journal of Transfusion Science ensures that invaluable research findings are readily accessible to all stakeholders, thereby bolstering collaborative efforts in transfusion science and related disciplines.
Hematology-American Society of Hematology Education Program
Fostering Excellence in Hematological ResearchHematology-American Society of Hematology Education Program is a premier peer-reviewed journal dedicated to advancing the field of hematology through comprehensive educational content. Published by the American Society of Hematology, this journal plays a crucial role in disseminating knowledge to researchers, clinicians, and students in hematology and related disciplines. With an impressive Q1 status in the field, it ranks among the top journals at the forefront of hematological research, as evidenced by its 60th percentile ranking in Scopus' Medicine - Hematology category. Although it does not offer open access, the journal provides invaluable insights and educational resources from leading experts, focusing on the latest advancements, treatment protocols, and evolving understanding of blood disorders. Covering a wide range of topics, from basic research to clinical applications, this journal is essential for anyone seeking to deepen their expertise and stay informed on the latest developments in hematology. For further engagement, readers can access insightful articles published since 2001, ensuring a rich repository of knowledge for ongoing research and clinical excellence.
Hematology Transfusion and Cell Therapy
Elevating standards in cell therapy and transfusion science.Hematology Transfusion and Cell Therapy, published by Elsevier, is a leading Open Access journal dedicated to advancing the fields of hematology, immunology, and transfusion medicine. Since its establishment in 2018, this journal has provided a vital platform for sharing innovative research and clinical advancements in the management of blood disorders and cellular therapies. Based in Brazil, it attracts a global audience, facilitating access to high-quality research that influences clinical practice and policy. With a current impact factor that places it in the Q3 category for both hematology and immunology as of 2023, the journal is recognized for its rigorous peer-review process and commitment to disseminating significant findings. By featuring a diverse range of articles, from original research to reviews, Hematology Transfusion and Cell Therapy aims to foster collaboration and knowledge sharing among researchers, professionals, and students alike, empowering them to tackle emerging challenges in their fields.
BLOOD
Connecting Scholars, Advancing Knowledge in Blood Research.BLOOD, published by the American Society of Hematology, is a premier peer-reviewed journal in the fields of Biochemistry, Cell Biology, Hematology, and Immunology. With an impressive impact factor and ranking in the top quartiles (Q1) across multiple disciplines, BLOOD is essential reading for researchers and professionals seeking to stay updated on the latest advancements in hematology and related fields. The journal has been a cornerstone of hematological research since its inception in 1946, providing a platform for rigorous scientific inquiry and discourse. Its commitment to publishing high-quality original research, comprehensive reviews, and insightful editorials makes it a vital resource for students, practitioners, and scientists alike. By offering exceptional access to influential publications, BLOOD continues to shape the future of hematology and enhance understanding of blood-related disorders, marking its vital role in advancing both basic and clinical research.
HemaSphere
Advancing hematology through open dialogue.HemaSphere, published by WILEY, stands at the forefront of hematology research, offering a vital platform for the dissemination of cutting-edge findings in the field. Since its inception in 2017 and official transition to Open Access in 2018, the journal has positioned itself as a leading conduit for high-impact research, maintaining a prestigious Q1 quartile ranking in the Hematology category as of 2023. Addressed in the United States at 111 River St, Hoboken, NJ, HemaSphere aims to foster a global dialogue among researchers, clinicians, and students by providing unrestricted access to high-quality content that encompasses clinical and experimental advancements. With an array of engaging articles, reviews, and commentaries, HemaSphere contributes significantly to the advancement of hematology, ensuring that critical knowledge is readily accessible to enhance patient care and innovative research. To explore the latest developments and breakthroughs in this dynamic field, we invite scholars, professionals, and students to engage with HemaSphere and elevate their understanding of hematologic science.
SEMINARS IN HEMATOLOGY
Connecting Scholars to Pioneering Hematological Research.SEMINARS IN HEMATOLOGY, published by W B SAUNDERS CO-ELSEVIER INC, stands as a premier academic journal dedicated to the field of hematology. Established in 1964, this journal has built a robust reputation over its nearly six-decade history, now recognized as a Q1 journal in Hematology with an impressive impact factor reflective of its high relevance and citation frequency within the academic community. Residents and scholars can access meticulously curated articles that address innovative research, clinical practices, and advancements in the understanding of blood disorders and treatment methodologies. The journal, ranked #36 out of 137 in the Scopus Medicine Hematology category, showcases cutting-edge research, ensuring its contributions are crucial for professionals, researchers, and students striving to stay at the forefront of the hematology field. Although not an Open Access journal, SEMINARS IN HEMATOLOGY continues to unite a global audience dedicated to advancing the science and clinical practices in hematology.